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Abstract
Background: Hepatitis B virus (HBV) genotypes can influence treatment outcome in HBV-monoinfected and human
immunodeficiency virus (HIV)/HBV-coinfected patients. Tenofovir disoproxil fumarate (TDF) plays a pivotal role in
antiretroviral therapy (ART) of HIV/HBV-coinfected patients. The influence of HBV genotypes on the response to
antiviral drugs, particularly TDF, is poorly understood.
Methods: HIV/HBV-co-infected participants with detectable HBV DNA prior to TDF therapy were selected from the
Swiss HIV Cohort Study. HBV genotypes were identified and resistance testing was performed prior to antiviral
therapy, and in patients with delayed treatment response (>6 months). The efficacy of TDF to suppress HBV
(HBV DNA <20 IU/mL) and the influence of HBV genotypes were determined.
Results: 143 HIV/HBV-coinfected participants with detectable HBV DNA were identified. The predominant HBV
genotypes were A (82 patients, 57 %); and D (35 patients, 24 %); 20 patients (14 %) were infected with multiple
genotypes (3 % A + D and 11 % A + G); and genotypes B, C and E were each present in two patients (1 %). TDF
completely suppressed HBV DNA in 131 patients (92 %) within 6 months; and in 12 patients (8 %), HBV DNA
suppression was delayed. No HBV resistance mutations to TDF were found in patients with delayed response, but
all were infected with HBV genotype A (among these, 5 patients with genotype A + G), and all had previously been
exposed to lamivudine.
Conclusion: In HIV/HBV-coinfected patients, infection with multiple HBV genotypes was more frequent than previously
reported. The large majority of patients had an undetectable HBV viral load at six months of TDF-containing ART. In
patients without viral suppression, no TDF-related resistance mutations were found. The role of specific genotypes and
prior lamivudine treatment in the delayed response to TDF warrant further investigation.
Background
Hepatitis B virus (HBV) infection is one of the most fre-
quent causes of end-stage liver disease. Due to shared
modes of transmission, coinfection with human immuno-
deficiency virus (HIV) and HBV is frequent, and represents
a global public health challenge [1]. HIV/HBV-coinfected
patients, particularly those with low CD4 cell counts,
are at increased risk for liver-related mortality [2–5].
Progression of HBV-related liver disease is influenced by
viral factors, such as viral load, genotype, the presence of
hepatitis B e antigen (HBeAg), and the appearance of es-
cape mutations [6–11].
The natural history of HBV infection in HIV-coinfected
individuals is modified by [5, 12]. nucleos(t)ide analogues
(NUCs), such as lamivudine (LAM), tenofovir disoproxil
fumarate (TDF), and emtricitabine (FTC), if used as com-
ponents of antiretroviral therapy (ART). Moreover, recent
studies showed that these HBV-specific agents not only
prevent liver deterioration, but can also lead to serocon-
version of HBeAg and even hepatitis B surface antigen
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(HBsAg) [12]. TDF, alone or combined with FTC, is a rec-
ommended component of an ART regimen for HIV/HBV-
coinfected patients because of its potent antiviral activity
against HIV and HBV and its excellent resistance profile
[13–15]. Indeed, no convincing evidence of HBV resist-
ance mutations against TDF has been described to date
[16]. Nevertheless, TDF and FTC fail to completely sup-
press HBV viral load in some HIV/HBV-coinfected pa-
tients [17, 18]. A recent long-term analysis of the effects of
TDF on HIV/HBV over 55 months showed a lack of viro-
logical response in 10 % of patients, who subsequently re-
quired entecavir rescue therapy [18].
HBV is classified into eight genotypes, designated A
to H, based on a sequence polymorphism of more than
8 % [19]. In HBV mono-infection, viral genotypes have
diverse geographical distribution, different routes of
infection, and are associated with distinct disease pro-
gression and treatment responses [20–22]. HBV geno-
type distribution in HIV/HBV coinfection appears to be
influenced by the route of infection, and to interfere
with the natural history of liver disease [6, 9–11, 23].
Importantly, some HBV genotypes may hamper the ef-
ficacy of NUCs in HBV-mono-infected patients [21].
We aimed to evaluate the impact of HBV genotype on
the efficacy of TDF in the treatment of HIV/HBV-coin-
fected patients.
Methods
Patient population
All patients were adults and were enrolled in the Swiss
HIV Cohort Study (SHCS), which is a large prospective
cohort study with continuous enrolment of HIV-
infected individuals and followed in HIV outpatient
clinics at 7 Swiss hospitals (Basel, Bern, Geneva, Lausanne,
Lugano, St. Gallen, Zurich) [24]. The institutional review
board of the Hospital where patients were recruited
(Zurich, Basel, Bern, Geneva, Lausanne, Lugano and St.
Gallen) approved the study and all subjects signed an
informed consent before enrollment in the study. Pa-
tients were followed every six months with a study visit
during which laboratory parameters were measured
and plasma samples taken. All data, including labora-
tory results, were transmitted to a data center and
plasma samples were stored at −80 °C. For this study,
the following demographic and clinical characteristics
were extracted: HBsAg, anti-HBc, HBeAg, anti-HBe,
anti-HDV, anti-HCV and HCV RNA viremia, sex, age,
date of first HIV test, route of transmission (risk
group), region of origin, ethnicity, HIV viremia, ART
(on treatment, off treatment, or treatment naïve), start
of first HIV treatment, CD4 cell counts, alanine trans-
aminase (ALT), aspartate transaminase (AST), inter-
national normalized ratio (INR), total bilirubin, serum
albumin and creatinine.
HBV analyses
Stored plasma samples taken before exposure to TDF
were selected and analyzed for HBV DNA. In patients
with detectable HBV DNA, it was amplified, HBV geno-
types identified, and resistance testing performed. DNA
was extracted using a commercially available extraction
kit (QIAamp DNA Mini Kit). Plasma samples of patients
were screened with an HBV SYBR real-time polymerase
chain reaction (PCR) analyser (realtime quantitative Cobas
AmpliPrep/Cobas Taqman HBV Test v1.0, Roche SA,
Switzerland) with a lower limit of detection of 20 IU/ml as
described previously [25]. This preliminary PCR allowed
us to screen for those samples with enough DNA to be
further analyzed.
For genotyping analysis, DNA was amplified by using
primers specific for the preS1/preS2 region of HBV (nu-
cleosides 3025 to 80 from the theoretical EcoR1 site of the
3,221-nucleotide HBV sequences) as described [26]. The
expected amplification product of 277 bp was used for
HBV genotyping by means of a direct sequencing analysis
using an automated sequencer (ABI Prism 3100, Applied
Biosystems, USA). Sequence data for the amplified region
of HBV-DNA were aligned with preS1/preS2 sequences
from among 80 GeneBank sequences of known genotype
representing eight HBV genotypes. Alignment of the se-
quences was performed with ClustalX software (version
1.81). Phylogenetic trees were constructed by the UPGMA
method with MEGA (version 4.0) [27]. If phylogenetic
analysis did not clearly determine the genotype, mostly
due to insufficient quality of the generating sequences, a
commercial line probe assay (InnoLiPa HBV genotype
v2.0 assay, Innogenetics, Ghent, Belgium), which deter-
mines the HBV genotype using specific sequences of
the S region of the HBV genome, was used to validate
the genotype.
For monitoring of drug resistance amplification of
DNA with a nested PCR approach was used. DNA of
the HBpol region was amplified with primers described
by Stuyver and coworkers [28], and sequenced as de-
scribed above. Data were analyzed using HepSEQ data-
base, a web-accessible, quality-based, molecular, clinical
and epidemiological database for hepatitis B. While ana-
lyzing the nested amplification product of 341 bp long,
the HepSEQ database assigns genotype and annotates
known resistance mutations.
If genotype analysis using both methods did not
match, generating genotype A on the preS region and
genotype G on the HBpol region, involvement of mixed
genotype infections was supposed. Primers described by
Osiowy et al. on the preS region contain mismatching
nucleotides for genotype G at the 3′ end and therefore
in mixed infections, amplification of genotype G was
poorer comparing to genotype A [29]. Based on HBV se-
quences on GeneBank, a new forward primer was
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designed to selectively amplify genotype G on the preS
region (100 % matching) to be used in addition of preS1R
as reverse primer. The sequence of this sense primer
pre S1GF was 5′-AGGTAGGAGTTGGAGCCTATGG-3′.
Amplifications conditions remained the same as described
and both genotypes could be amplified.
Three patients showing mixed infections (genotype A and
D) with preS and HBpol region were confirmed to be mixed
infection with commercial Inno-Lipa HBV genotyping.
Efficacy of TDF on HBV suppression
The efficacy of TDF to suppress HBV was defined as
HBV DNA below the limit of detection (<20 IU/mL) as
assessed with patients belonging to the Cohort on the
routine basis, within six month from start of treatment.
In patients where complete HBV suppression was not
achieved with TDF, HBV subtype and treatment history
were determined and repeated post-TDF plasma samples
were analyzed for HBV viremia and genotypic resistance.
Statistical methods
Fisher’s exact test and non-parametric Mann–Whitney
U-test were used for comparison of categorical and con-
tinuous variables, respectively. Statistics were computed
using Stata 11/SE (StataCorp LP, College Station, Texas,
77845 USA). All tests were two-tailed with significance
level at 0.05.
Results
Analysis population and baseline characteristics
In 2008, a total of 15,139 participants were included in the
SHCS and, of these, 7,038 were on follow-up. Of these,
3,492 (49.6 %) had anti-HBc positive status, and 388 had
positive HBsAg serology (11 %). Of the HBsAg-positive
participants, 271 had been exposed to TDF (Fig. 1). HBV
DNA was detectable in 143 and undetectable in 128 per-
sons before the initiation of TDF.
Baseline data for the 271 TDF-treated patients included
in this analysis are summarized in Table 1. Patients with
or without detectable HBV DNA were comparable; no dif-
ferences were found for baseline demographic parameters
(data not shown). Also, baseline clinical characteristics
were similar between the two groups with the exception of
median serum ALT levels of patients with detectable HBV
DNA (slightly above normal at 47 IU/L (range 11–
1020 IU/L, normal < 45 IU/L)), with no statistical differ-
ences observed between the genotypes.
HBV genotype distribution
HBV DNA was extracted and the HBV genotype deter-
mined in all 143 patients with detectable HBV DNA.
Genotype was determined by phylogenetic analyses in
120 patients and by a commercial line probe assay in 23
patients. The predominant genotypes were A (82 pa-
tients, 57 %) and D (35 patients, 24 %). 20 patients
(14 %) were infected with multiple genotypes (4 patients
(3 %) A + D; 16 patients (11 %) A +G). Genotypes B, C
and E were each present in two individuals (1 %)
(Table 2). The genotype distribution varied among the
transmission risk groups: Genotype A was most preva-
lent in men who have sex with men (MSM; 66 patients,
46 %), followed by the heterosexual transmission group
(22 patients, 15 %), whereas genotype D was predomin-
ant in intravenous drug users (IDU; 25 patients, 17 %)
Fig. 1 Analysis population
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(p = 0.02) (Table 2). The majority of multiple HBV geno-
type infections was found in MSM (13/20, 65 %) and
was less common in heterosexual persons (4/20, 20 %),
or in IDUs (2/20, 10 %).
In one patient, a genotype D infection with a high
HBV DNA level (200,000 IU/mL) was detected in 2003
before he received drugs active against HBV. Later he
was treated with pegylated interferon for 6 months and,
one year later, received a combination of LAM and TDF
for 16 months and then stopped for a structured treat-
ment interruption (STI) of the ART. When the STI
started, HBV DNA was suppressed and telbivudine
treatment was initiated; at this point the HBV genotype
was A + G. Six months later, HBV DNA became slightly
positive (511 IU/mL) and the detected genotype was
A + G +D. No HBV resistance mutations were detected
in this patient.
HDV and HCV co-infection
HDV serology was tested in 38 patients and it was posi-
tive in 13 patients (34 %). HBV genotype was determined
in 9 out of 13 HDV positive patients, 6 were genotype A
and 3 genotype D. Furthermore HCV serology was
known in 141 individuals; anti-HCV was identified in 31
Table 1 Baseline demographic and clinical characteristics of TDF-treated HIV/HBV co-infected patients
143 patients 128 patients
Detectable HBV DNA Undetectable HBV DNA
Origin: Caucasian 121 (84 %) 88 (68 %)
African 16 (11 %) 36 (28 %)
Asian 10 (4 %) 4 (3 %)
Age in years (median) (range) 41 (23–73) 40 (21–75)
Sex M:F 122 (85 %):21 (15 %) 101 (79 %):27 (21 %)
CD4 count (median) (range) 295 (6–1143) 326 (21–1512)
HIV viremia (median) log10 cp/ml (range) 2.84 (0–6.08) 1.74 (0–6.01)
HIV treatment on HAART 82 (57 %) 84 (66 %)
treatment naïve 31 (22 %) 15 (12 %)
off HAART 30 (21 %) 29 (23 %)
Hepatitis delta infection positive 9 4
negative 17 8
missing data 117 116
HCV coinfection positive 31 37
negative 110 87
missing data 2 4
ALT (median) IU/ml (range) IU/ml 47 (11–1020) 32 (7–284)
AST (median) IU/ml (range) IU/ml 35 (19–375) 33 (14–135)
INR (median) (range) 1 (0.9-2.6) 1 (0.9-1.2)
Total Bilirubin (median) umol/L (range) 9 (4–243) 9 (2–30)
(range) 39 (20–49) 39 (32–52)
(range) 77 (37–214) 76 (41–150)
Table 2 Distribution of HBV genotypes of TDF-treated HIV/HBV
co-infected patients
Genotype Heterosexual IVDU MSM Other Unknown
A 22 3 53 2 2
n = 82 (57 %)
A + D 1 1 2 0 0
n = 4 (3 %)
A + G 3 1 11 0 1
n = 16 (11 %)
B 1 0 1 0 0
n = 2 (1 %)
C 2 0 0 0 0
n = 2 (1 %)
D 5 25 4 0 1
n = 35 (24 %)
E 2 0 0 0 0
n = 2 (1 %)
Total n = 143 36 (25 %) 30 (21 %) 71(50 %) 2 (1 %) 4 (3 %)
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patients (22 %) and HCV RNA was measurable in nine
of these patients (median 2.6 ×106 copies/mL). The ma-
jority of HIV/HCV/HBV co-infected patients (23 pa-
tients, 74 %) were HBV genotype D-infected, while a
smaller group (8 patients, 26 %) was HBV genotype A-
infected (4 A, 2 A + D and 2 A + G). Of the 9 viremic
HCV-infected patients, 8 (89 %) had HBV genotype D
and one patient had HBV genotype A + D.
HBV genotypic resistance testing
In all 143 patients genotypic resistance testing was per-
formed. In three patients, there was insufficient HBV
DNA to perform resistance testing. Prior to TDF initi-
ation, 89/143 patients (62 %) had wild type virus without
mutations and 54/143 patients (38 %) had LAM-
resistance mutations (Table 3). In follow-up samples
from 12 patients who exhibited a delayed response to
TDF, genotypic mutations were detected in four, al-
though no resistance associated mutations against TDF
were identified (see below).
Efficacy of TDF on HBV suppression
In 131 patients (92 %), TDF completely suppressed HBV
DNA below the limit of detection (<20 IU/mL) within
6 months, while in 12 patients (8 %) suppression of HBV
DNA was delayed (Table 4). In the 12 patients with a de-
layed response to TDF, HBV was detectable between 28
and 132 weeks after TDF initiation. All 12 patients were
infected with HBV genotype A (5 [42 %] A + G) and pre-
viously exposed to LAM. Of the 131 patients 119 (91 %)
were previously exposed to LAM, thus there is no differ-
ence in LAM exposure in the two groups (p = 0.6). In
eight of the 12 patients (67 %), no genotypic resistance
was detected, while in four known genotypic resistances
were identified; three patients had pre-existing resistance
mutations prior to TDF treatment and one exhibited a
changing pattern of resistance over time (Table 4); no re-
sistance mutations to TDF were detected.
One patient, who was treated for many years with
LAM, harbored a L180M, M204V mutation six months
after initiating TDF treatment (Table 4, Case 1). After
29 months of TDF treatment, HBV-DNA was detectable
and the virus changed to a L180M, M204I genotype. An-
other patient was treated with LAM for 9 years (1995–
2004) before it was discontinued due to HIV resistance
(Table 4, case 8). In October 2006, the identified virus was
wild type (no resistance) and TDF/FTC combination
therapy was initiated in November 2006. Six month after
initiation, the patient remained viremic and harbored a
triple resistance (V173L, L180M, M204V). After a further
8 months of treatment, HBV DNA remained positive and
a double mutation (L180M, M204V) was detected.
Discussion
In the Swiss HIV Cohort study, HBV genotype A was pre-
dominant in HIV/HBVco-infected participants, followed
by genotype D, which is consistent with previous reports
[10, 11, 30]. There was no difference in the HBV genotype
distribution between different ethnicities, but genotypes
differed between HIV transmission risk groups: The ma-
jority of HBV genotype A infection was found in MSM
whereas IDU was associated with genotype D, which is
consistent with data from the EuroSIDA study [11]. More-
over, HBV genotype D infection was predominant in HIV/
HBV/HCV triple infection (73 %), and was present in all
patients with chronic HCV infection. In contrast to the
EuroSIDA study, in the present study, HBV genotyping
was performed by direct sequencing of the preS1 gene
with subsequent phylogenetic analyses and a commercial
hybridization line probe assay was used only in cases
where phylogenetic analysis was inconclusive. As the re-
sults of the studies are generally in accordance it could be
argued that the easier analysis with the commercial
hybridization assay is as effective as the time-consuming
direct sequencing approach. On the other hand, a greater
number of cases of multiple HBV genotype infection were
detected in our study, which could be due to the differ-
ences in sequencing approaches. In our study, multiple
HBV genotype infections were identified in 20 patients
(14 %), which were all in combination with genotype A
(16 A +G and 4 A +D). Mixed infection with different
HBV genotypes, subgenotypes and recombinations have
been increasingly described especially in highly endemic
Asian countries, like China [31] and Thailand [32]. In a re-
cent study from Laos, 5.8 % of 446 HBsAg positive blood
donors were infected with multiples HBV genotypes [33].
Dual infection (A +D, A +G, and D +G) has also been re-
ported in 8 out of 241 patients (3.3 %) from Germany [34]
or in a report from Canada [29].
Table 3 Distribution of resistance mutations prior to TDF
treatment in HIV/HBV co-infected patients
n n HBV genotype
M204V 1 1 D
L180M +M204V 30 22 A
5 A + G
1 A + D
2 D
L180M +M204I 7 3 D
4 D
V173L + L180M +M204V 16 12 A
1 D
1 C
1 A + G
1 A + D
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Treatment with TDF resulted in complete suppression
of HBV DNA in 92 % of patients within 6 months, and a
delayed decline in HBV DNA was observed in 12 patients
(8 %). No HBV resistance mutation to TDF was found to
explain the delayed response, which is consistent with
previous studies [16, 35]. Nevertheless, delayed viral sup-
pression or even incomplete HBV-DNA control during
prolonged antiviral treatment has been recently described
with several reasons for explanation [35, 36] as poor ad-
herence to therapy, altered HBV-specific T cell response in
Table 4 Treatment details, viremia and genotypic resistance in HIV/HBV co-infected patients with a delayed response to TDF treatment
Case HBV genotype HBV drug TDF start date weeks on TDF HBV viremia (cp/ml) date analyses genotypic resistance
1 A exposed to LAM NA no sample available
TDF 3-Jan-05 NA no sample available
24 4630 21-Jun-05 L180M M204V
101 NA 13-Dec-06 L180M M204V
132 NA 15-Jul-07 L180M M204I
2 A + G exposed to LAM 200000 Before TDF No resistance
TDF 20-May-04 200000 no sample available
125 99 10-Oct-06 No resistance
3 A + G exposed to LAM NA no sample available
TDF 18-Apr-05 920 no sample available
116 1520 9-Jul-07 No resistance
4 A exposed to LAM 317′000′000 Before TDF V173L L180M M204V
TDF 14-Mar-06 186′000′000 no sample available
39 273 12-Dec-06 V173L L180M M204V
TDF + FTC 28-Jun-07 100 29 14-Feb-08 V173L L180M M204V
5 A exposed to LAM NA no sample available
TDF 23-Aug-05 NA no sample available
93 207 6-Jun-07 No resistance
6 A + G exposed to LAM 100′000′000 Before TDF No resistance
TDF 18-Jan-06 1′008′000 no sample available
7 A exposed to LAM 793′000′000 Before TDF V173L L180M M204I
TDF + FTC 28-Apr-06 NA no sample available
47 240 20-Mar-07 V173L L180M M204V
73 NA 19-Sep-07 V173L L180M M204V
8 A exposed to LAM 11′000′000 Before TDF No resistance
TDF + FTC 9-Nov-06 28 NA 21-May-07 V173L L180M M204V
66 913 12-Feb-08 L180M M204V
9 A + G exposed to LAM NA Before TDF No resistance
TDF 25-Sep-06 9′000′000 no sample available
43 55 23-Jul-07 No resistance
10 A exposed to LAM 764′690′000 Before TDF No resistance
TDF 30-Mar-07 38′291 no sample available
37 252 17-Dec-07
11 A + G exposed to LAM 1′100′000′000 Before TDF No resistance
TDF + FTC 2-Feb-07 727′000 no sample available
36 128′000 9-Oct-07 No resistance
12 A exposed to LAM 75 Before TDF No resistance
TDF 5-Feb-07 49 no sample available
28 NA 20-Aug-07
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HIV infection [37] and the rt194T polymerase mutation
[38]. However, if the viral genotype influences this setting
has not yet examined. In our study, all 12 patients were
HBV genotype A-infected and five (42 %) had a double
HBV genotype A +G infection. In addition, all patients had
been previously treated with LAM. In a recent study, a
delayed response to TDF was observed in 15 % of HIV/
HBV-co-infected patients who added TDF to LAM. In
these patients with a delayed response to TDF no resistance
to TDF was detected, which is consistent with the findings
of the present study [39]. Moreover, Boyd et al., described
again recently that 14 % of co-infected HIV/HBV infected
patients had detectable viral load even 12 month after start
of TDF without identifying specific mutations in the poly-
merase gene which may explain this delay [35]. Interest-
ingly, in this study HBV genotype is available in many, but
not all patients and 63 % of patient with transient viremia
were genotype A and even more 77 % of patients with per-
sistent high or low level viremia [35]. This high numbers of
genotype A in “difficult to treat patients” were not further
discussed but indicate towards our findings. Furthermore, a
chart review of 31 HIV/HBV-coinfected patients reported a
shorter time to suppression of HBV DNA in LAM-naive
patients treated with TDF and FTC (n = 12) compared with
patients in whom LAM had previously failed (n = 19) [40].
The median time to complete suppression of HBV was
466 days in the LAM-naive group compared with 877 days
in patients who had previously received LAM (P = 0.001).
After 24 months, 5/5 (100 %) LAM-naive patients had an
undetectable HBV DNA level compared with 4/13 (31 %)
prior-LAM patients (P = 0.015). However, the influence of
HBV genotype on TDF + FTC efficacy was not reported.
Taken together, in our study we found a common viro-
logical characteristic, present in all patients that had a
delayed antiviral response to TDF. The definition of
HBV genotype is a sequence polymorphism difference of
more than 8 % of the genome [19] and this may play a
role in the immunological control [41] that is clearly
needed in the antiviral treatment with TDF. Neverthe-
less, this hypothesis of different immune regulation
needs to be confirmed in larger studies and linked to
other parameters as pretreatment LAM mutations.
Our study has limitations due to the retrospective na-
ture of the analysis. Notably, it was not possible to com-
pare the status of liver disease (histology or transient
elastography) together with the genotype distribution
and correlate this with liver disease progression, as these
data were not available in the database. However, the
high number of coinfected patients and the accuracy of
genotype analyses added strength to the study.
Conclusion
In conclusion, these data confirm that the most frequent
HBV genotype in HIV/HBV-coinfected patients is genotype
A, followed by genotype D, and that the genotype distri-
bution is associated with the risk for HIV acquisition. Our
results also suggest that a higher proportion of multiple
HBV genotype infections may be present in HIV/HBV-
coinfected patients than previously reported. In addition,
our results demonstrated complete suppression of HBV
DNA in 92 % of TDF-treated patients within 6 months, yet
a minority of patients (8 %) exhibited a delayed virological
response to TDF but all without HBV resistance mutations.
Know parameters as prior LAM treatment with selected
mutations or poor drug adherence, may influence TDF re-
sponse even if HBV genotypes A infection as found in this
cohort could explain this delay and may have clinical im-
pact but warrants further investigation.
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